n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide has been researched along with Neutropenia in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beijnen, JH; Dittrich, C; Huitema, AD; Schellens, JH; Wanders, J; Zandvliet, AS | 1 |
| Beijnen, JH; Copalu, W; Huitema, AD; Schellens, JH; Zandvliet, AS | 1 |
| Beijnen, JH; Cendrós, JM; Friberg, LE; Huitema, AD; Karlsson, MO; Keizer, RJ; Obach, R; Peraire, C; Schellens, JH; Soto, E; Trocóniz, IF; Wanders, J | 1 |
| Bhattacharya, N; Costello, R; DeRosa, C; Faucher, J; Haddad, RI; Latham, VM; Loda, M; Miller, LP; Oster, MW; Posner, MR; Raftopoulos, H; Shapiro, GI; Weinstein, LJ; Wieczorek, TJ; Yule, M; Zhang, X | 1 |
| Armand, JP; Beijnen, JH; Dittrich, C; Droz, JP; Dumez, H; Fumoleau, P; Huitema, AD; Karlsson, MO; Mathôt, RA; Punt, CJ; Ravic, M; Raymond, E; Roché, HH; Schellens, JH; van Kesteren, C; Wanders, J; Yule, SM; Zandvliet, AS | 1 |
| Dittrich, C; Gneist, M; Huitema, AD; King, AA; Wanders, J; Zandvliet, AS | 1 |
| Beijnen, JH; Copalu, W; Etienne-Grimaldi, MC; Huitema, AD; Milano, G; Schellens, JH; Siegel-Lakhai, WS; Zandvliet, AS | 1 |
| Campone, M; Faber, MN; Fumoleau, P; Punt, CJ; Ravic, M; van de Walle, B | 1 |
5 trial(s) available for n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide and Neutropenia
| Article | Year |
|---|---|
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Discovery; Female; Humans; Leukocyte Count; Male; Middle Aged; Models, Biological; Neutropenia; Predictive Value of Tests; Sulfonamides; Treatment Outcome | 2011 |
A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle
Topics: Aged; Aged, 80 and over; Anemia; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Patient Dropouts; Phosphorylation; Proliferating Cell Nuclear Antigen; Retinoblastoma Protein; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2004 |
A phase I and pharmacokinetic study of indisulam in combination with carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Sarcoma; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2007 |
PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Male; Middle Aged; Models, Biological; Neutropenia; Sulfonamides | 2008 |
Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG).
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2001 |
3 other study(ies) available for n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide and Neutropenia
| Article | Year |
|---|---|
Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2008 |
Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Body Surface Area; Clinical Trials as Topic; Computer Simulation; Cytochrome P-450 Enzyme System; Cytotoxins; Female; Hematologic Diseases; Humans; Male; Middle Aged; Models, Biological; Models, Statistical; Neutropenia; Racial Groups; Risk; Risk Factors; Sex Factors; Sulfonamides; Thrombocytopenia; Young Adult | 2009 |
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Models, Biological; Neutropenia; Sulfonamides; Thrombocytopenia | 2005 |